Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Synthetic Biologics stock
Learn how to easily invest in Synthetic Biologics stock.
Synthetic Biologics Inc is a biotechnology business based in the US. Synthetic Biologics shares (SYN) are listed on the NYSE MKT and all prices are listed in US Dollars. Synthetic Biologics employs 16 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Synthetic Biologics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – SYN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Synthetic Biologics stock price (NYSE MKT: SYN)Use our graph to track the performance of SYN stocks over time.
Synthetic Biologics shares at a glance
|Latest market close||$0.99|
|52-week range||$1.05 - $4.90|
|50-day moving average||$1.44|
|200-day moving average||$2.29|
|Wall St. target price||$6.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.12|
Buy Synthetic Biologics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Synthetic Biologics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Synthetic Biologics price performance over time
|1 week (2022-09-23)||-6.98%|
|1 month (2022-09-01)||-32.93%|
|3 months (2022-07-01)||328.70%|
|6 months (2022-03-28)||N/A|
|1 year (2021-10-01)||117.13%|
|2 years (2020-10-01)||113.00%|
|3 years (2019-10-01)||120.29%|
|5 years (2017-09-29)||5.67%|
Synthetic Biologics financials
|Gross profit TTM||$0|
|Return on assets TTM||-13.92%|
|Return on equity TTM||-26.26%|
|Market capitalisation||$16.8 million|
TTM: trailing 12 months
Synthetic Biologics share dividends
We're not expecting Synthetic Biologics to pay a dividend over the next 12 months.
Have Synthetic Biologics's shares ever split?
Synthetic Biologics's shares were split on a 1:10 basis on 24 July 2022. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Synthetic Biologics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Synthetic Biologics shares which in turn could have impacted Synthetic Biologics's share price.
Synthetic Biologics share price volatility
Over the last 12 months, Synthetic Biologics's shares have ranged in value from as little as $1.05 up to $4.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Synthetic Biologics's is 1.3156. This would suggest that Synthetic Biologics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Synthetic Biologics overview
Synthetic Biologics, Inc. , a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004.
Synthetic Biologics in the news
Synthetic Biologics Announces Presentation at SIOP International Society of Pediatric Oncology on New Preclinical Data Supporting Evaluation of VCN-01 and Topotecan for the Treatment of Refractory Retinoblastoma
Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck
Frequently asked questionsWhat percentage of Synthetic Biologics is owned by insiders or institutions?
Currently 1.98% of Synthetic Biologics shares are held by insiders and 8.715% by institutions. How many people work for Synthetic Biologics?
Latest data suggests 16 work at Synthetic Biologics. When does the fiscal year end for Synthetic Biologics?
Synthetic Biologics's fiscal year ends in December. Where is Synthetic Biologics based?
Synthetic Biologics's address is: 9605 Medical Center Drive, Rockville, MD, United States, 20850 What is Synthetic Biologics's ISIN number?
Synthetic Biologics's international securities identification number is: US87164U2015 What is Synthetic Biologics's CUSIP number?
Synthetic Biologics's Committee on Uniform Securities Identification Procedures number is: 724153101
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert